© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
Skylar Jeremias
June 5 2022
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Celltrion’s Infliximab Biobetter Shows Significant Clinical Improvements Over Original Biosimilar Version
Skylar Jeremias
June 4 2022
Results from the European Congress of Rheumatology’s annual meeting revealed that Celltrion’s Remsima SC, a subcutaneous biobetter infliximab product, produced better clinical outcomes compared with the original Remsima, an infliximab biosimilar delivered intravenously.
Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
Skylar Jeremias
May 22 2022
The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
Skylar Jeremias
May 18 2022
Altering reimbursement procedures needs to become a bigger priority for government officials to incentivize biosimilar utilization, according to Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System.
Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics
Skylar Jeremias
May 14 2022
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.
Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists
Skylar Jeremias
May 8 2022
Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei
Laura Joszt
May 3 2022
The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.
Dr Eric Tichy Details Why More State Biosimilar Bills Are Needed
Skylar Jeremias
May 1 2022
AMCP: Academy of Managed Care Pharmacy
Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System, discusses the importance of state legislation to boost biosimilar access and uptake.
AMCP Posters Highlight Clinical, Real-world Application of Trastuzumab, Infliximab Biosimilars
Skylar Jeremias
April 23 2022
AMCP: Academy of Managed Care Pharmacy
Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting highlighted the clinical similarity of a trastuzumab biosimilar compared with its reference product and real-world longitudinal application of infliximab biosimilars.
